The French National Research Agency, in partnership with 16 countries is launching a 9th joint transnational call for proposals through the ERA-NET EuroNanoMed (ENM) on Nanomedicine.
The goal of this call for proposals is to both support translational research projects that combine innovative approaches in the field of Nanomedicine and to encourage and enable transnational collaboration between public and private research groups from academia, clinical/public health research or research teams from industrial enterprises (all sizes). The participation of Medical Doctors and SMEs will be strongly encouraged. This call for proposals includes funding research organisations of 16 countries (Belgium, Canada, Estonia, France, Germany, Greece, Israel, Italy, Latvia, Lithuania, Poland, Romania, Slovakia, Spain, Taiwan, and Turkey).
Project proposals will need to cover at least one of the following areas that are equal in relevance for this call:
The projects should fall within Technology Readiness Levels (TRL) 3-6, although for being realistic and coherent with the characteristics of the call, projects should propose advancements for a maximum of two TRL levels during their lifetime.
A consortium applying to this call will be required to include research group(s) from at least 2 of the 3 following categories:
Only transnational projects will be funded. Each consortium submitting a proposal will need to involve a minimum of 3 eligible and a maximum of 5 eligible partners from at least 3 different countries participating to the call. The project coordinator must be eligible to be funded by EuroNanoMed III participating countries/regions. No more than 2 eligible partners from the same country participating in the call will be accepted in one consortium.
Research groups not eligible to be funded (e.g. from non-funding countries or not fundable according to national/regional regulations of the participating funding countries) may participate in transnational projects if they are able to secure their own funding. However, no more than one research group with own funding will be included in a consortium and the coordinator will need to be eligible to be funded by the participating funding organisations to the call.
The maximum number of partners will possibly be increased from 5 to 7 (including eligible for funding and non-eligible for funding research groups) if partners from these participating countries, which are either new in the EuroNanoMed consortium or their community has been under-represented in past EuroNanoMed calls: Estonia, Latvia, Lithuania, Romania, Slovakia, Taiwan)